GeoVax Labs | 8-K: FY2026 Q2 Revenue: USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.97, beating the estimate of USD -2.155.

EBIT: As of FY2026 Q2, the actual value is USD -4.442 M, beating the estimate of USD -5.319 M.

Financial Performance Overview

Net Loss

GeoVax Labs, Inc. reported a net loss of - $4,426,578 for the three-month period ended June 30, 2026, compared to - $5,369,783 for the comparable period in 2025. For the six-month period ended June 30, 2026, the net loss was - $9,688,499, compared to - $10,727,434 for the same period in 2025.

Revenue from Government Contract

No revenue from government contracts was recognized during the three-month and six-month periods ended June 30, 2026. This compares to $852 thousand in the three-month period and $2,489 thousand in the six-month period ended June 30, 2025, which were associated with the Biomedical Advanced Research and Development Authority (BARDA) contract for the GEO-CM04S1 COVID-19 vaccine program. The BARDA contract was terminated for convenience to the government in April 2025.

Operating Expenses

• Research and Development Expenses: These expenses were $3,110 thousand for the three-month period and $7,014 thousand for the six-month period ended June 30, 2026. This represents a decrease from $4,729 thousand and $10,083 thousand for the comparable periods in 2025, respectively. The decrease primarily reflects lower costs from discontinued activities related to the BARDA contract and reduced spending on GEO-CM04S1 clinical activities.
• General and Administrative Expenses: These expenses were $1,332 thousand for the three-month period and $2,701 thousand for the six-month period ended June 30, 2026. This is down from $1,542 thousand and $3,230 thousand for the comparable periods in 2025, respectively. This decrease was mainly due to lower investor relations consulting costs and reduced stock-based compensation expense.

Loss from Operations

Loss from operations for the three months ended June 30, 2026, was - $4,442 thousand, compared to - $5,419 thousand for the same period in 2025. For the six months ended June 30, 2026, loss from operations was - $9,715 thousand, compared to - $10,824 thousand for the same period in 2025.

Interest Income

Interest income was $15 thousand for the three-month period and $26 thousand for the six-month period ended June 30, 2026. This compares to $49 thousand and $97 thousand for the comparable periods in 2025, respectively.

Cash Position

GeoVax Labs, Inc. reported cash and cash equivalents of $3,143 thousand as of June 30, 2026, a slight increase from $3,086 thousand as of December 31, 2025.

Balance Sheet Information

• Total Current Assets: $4,175 thousand as of June 30, 2026, down from $5,315 thousand as of December 31, 2025.
• Total Assets: $4,643 thousand as of June 30, 2026, compared to $6,342 thousand as of December 31, 2025.
• Total Liabilities: $2,882 thousand as of June 30, 2026, up from $2,517 thousand as of December 31, 2025.
• Stockholders’ Equity: $1,761 thousand as of June 30, 2026, compared to $3,825 thousand as of December 31, 2025.

Common Shares Outstanding

Common shares outstanding were 7,369,243 as of June 30, 2026, significantly higher than 1,732,147 as of December 31, 2025.

Operational Metrics and Business Update

GEO-MVA Program

GeoVax Labs, Inc. advanced multiple operational initiatives during the second quarter of 2026 to support the planned fourth-quarter initiation of the GEO-MVA pivotal immunobridging study under an expedited regulatory pathway with the European Medicines Agency (EMA). Activities included clinical operations planning, utilization of previously manufactured cGMP clinical trial material, and advancement of the AGE1® continuous cell-line manufacturing platform. GeoVax Labs, Inc. believes GEO-MVA is uniquely positioned to address the growing need for diversified global MVA vaccine manufacturing capacity for public health preparedness and biodefense.

Gedeptin® Immuno-Oncology Program

GeoVax Labs, Inc. continued advancing Gedeptin, its investigational gene-directed enzyme prodrug therapy, towards combination immunotherapy strategies aimed at enhancing immune checkpoint inhibitor activity in solid tumors. The company is strengthening the program’s strategic positioning through its exclusive intellectual property license from Emory University covering Gedeptin in combination with immune checkpoint inhibitors.

Strategic Reprioritization

In May 2026, GeoVax Labs, Inc. announced a strategic reprioritization of its development portfolio to concentrate resources on its lead programs, GEO-MVA and Gedeptin. This decision included discontinuing active development activities for the GEO-CM04S1 COVID-19 vaccine candidate. This reflects the evolving COVID-19 vaccine market and a focus on programs with clearer regulatory pathways and stronger demand visibility.

Outlook and Guidance

GeoVax Labs, Inc.’s priorities include completing activities for the GEO-MVA pivotal immunobridging study, maintaining disciplined capital allocation, and positioning GEO-MVA to meet global demand for MVA vaccine supply. The company aims for successful execution of the GEO-MVA program while building long-term value across infectious diseases and oncology through Gedeptin. Strategic priorities also include advancing scalable manufacturing capabilities, engaging for future government and international procurement opportunities, and advancing Gedeptin combination immunotherapy strategies.